Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Axitinib + Pembrolizumab & Clear Cell Renal Cell Carcinoma (ccRCC), Axitinib + pembrolizumab is approved by both the FDA and EMA as a first-line treatment for advanced or metastatic clear cell renal cell carcinoma (ccRCC). This combination became a standard frontline therapy following the KEYNOTE-426 phase III trial, which demonstrated superior overall survival and progression-free survival compared to sunitinib monotherapy in patients with advanced ccRCC (1, 2, 3…